MedTrace Logo

Betadine Versus Saline in Swapping of Subcutaneous Tissue

NCT06595823 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2024-09-23

No results posted yet for this study

Summary

Caesarean section is an increasingly common major surgical procedure performed on women. Last decade an overall increase of the global rate of caesarean section, of up to 31.2%, was reported. The risk of maternal morbidity and mortality is higher in caesarean section than in vaginal birth; postoperative infection is a common component of morbidity. With the increase in caesarean section, it is important that the risks to the mother are minimized as far as possible.

Women who give birth by caesarean section are exposed to both endogenous (internal) and exogenous (external) sources of infection during birth. Exposure to a hospital environment places these women at risk of developing hospital-acquired infections. The rate of post-caesarean infection has been estimated to be 10 times greater than that after vaginal birth.

Conditions

  • Surgical Site Infection

Interventions

DRUG

Betadine

To compare between Betadine (10%) and saline (0.9%) in swapping of subcutaneous tissue for prevention of surgical site infection after primary elective caesarian section.

Sponsors & Collaborators

  • Al-Azhar University

    collaborator OTHER

  • Egymedicalpedia

    lead INDUSTRY

Principal Investigators

  • Ahmed Abd El Hameed Ahmed, Professor · Obstetrics and Gynecology Department, Faculty of medicine, Al-Azhar University, Assuit.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-10
Primary Completion
2023-03-05
Completion
2023-03-10

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06595823 on ClinicalTrials.gov